Japan PPI inflation slips to 11-mth low in July
Investing.com - Cyteir Therapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Cyteir Therapeutics announced earnings per share of $-0.31 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.40 on revenue of $0.00.
Cyteir Therapeutics 's are down 5.02% and is trading at $1.75 , still down 90.08% from its 52 week high of $17.65 set on Thursday, November 11, 2021.
Cyteir Therapeutics follows other major Healthcare sector earnings this month
Cyteir Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar